PowerShares Intl Div Achiev ETF
Most Recent
Earnings ReportShire: Why Analysts Expect Revenue Growth in Q3 2018
Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1.
Company & Industry OverviewsAssessing Novartis’s Performance in October So Far
Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.
Company & Industry OverviewsA Look at Shire’s Valuation on September 19
Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise.
Company & Industry OverviewsNovartis’s Valuation in August
Novartis (NVS), a leading pharmaceutical company, reported EPS of $1.29 on revenues of $13.2 billion in Q2 2018, a 5% growth year-over-year.
Company & Industry OverviewsNovartis’s Innovative Medicines Business in 4Q17
Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues.
Earnings ReportPerformance of Sanofi’s Business Segments in 4Q17
Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17 for 8.7% growth in operating revenues compared to its 4Q16 revenues.
Company & Industry OverviewsHow Wall Street Reacted to Berkshire Hathaway Investment in Teva
Teva Pharmaceuticals stock rose ~10.5% during the morning of February 15, 2018, before closing at a rise of ~7.7% on the day.
Company & Industry OverviewsAnalysts’ Updates after Sanofi’s Bioverativ Announcement
In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.
Company & Industry OverviewsExploring Bioverativ’s Business Profile and Market Presence
Bioverativ completed its spin-off from Biogen (BIIB) in February 2017. Bioverativ is expected to register 30% growth in 2017.
MiscellaneousPBA’s Dividends: Key Drivers
Pembina Pipeline Corporation (PBA) offers transportation and midstream services in North America. Its revenue fell 8% in 2016 before gaining 22% in 9M17.
MiscellaneousTRP’s Dividends: Key Drivers
TransCanada Corporation (TRP) is an energy infrastructure company in North America. Its revenue grew 11% in both 2016 and 9M17.
MiscellaneousWhat Could Continue to Drive ENB’s Dividends
Enbridge (ENB) is involved in energy transportation in the United States and Canada. Revenue grew 2% in 2016, compared to 25% in 9M17.
Earnings ReportNovartis’s 4Q17 Earnings: Sandoz Business
Sandoz reported a decline of 4.0% in operating revenues, offset by a 4.0% positive impact of foreign exchange.
Company & Industry OverviewsHow Sanofi Can Benefit from Ablynx Acquisition
On January 29, 2018, Sanofi entered an agreement with Ablynx where Sanofi will acquire all of the outstanding ordinary shares of Ablynx.
Company & Industry OverviewsHow Is Novartis’s Subsidiary Sandoz Positioned for 2018?
In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) subsidiary Sandoz generated revenues of $2.4 billion, $2.5 billion, and $2.6 billion, respectively.
Earnings ReportBehind Novartis’s 4Q17 Estimates: Innovative Medicines
The Innovative Medicines segment is expected to report growth in operating revenues for 4Q17.
Company & Industry OverviewsBehind Sanofi’s Generics and Consumer Healthcare Business in 3Q17
Sanofi’s (SNY) general medicines and emerging markets sub-segment reported revenues of 433 million euros in 3Q17, representing a 0.9% YoY fall.
Company & Industry OverviewsHow Did Teva’s CNS Portfolio Perform in 3Q17?
Teva CNS drugs generated 3Q17 revenues of $1.1 billion, which was ~12% lower YoY (year-over-year) and ~1% lower QoQ (quarter-over-quarter).
Energy & UtilitiesHow Did Cimarex Energy’s Dividend Cut Affect Its Dividend Yield?
Cimarex Energy’s (XEC) revenues fell 40.0% and 13.0% in 2015 and 2016, respectively.
Company & Industry OverviewsBehind Sanofi’s 3Q17 Revenue Growth
Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.
Company & Industry OverviewsBehind Methanex’s Long-Term Agreement with Painted Pony Energy
On November 8, Methanex announced that it entered into a 14-year agreement with Painted Pony Energy for natural gas supplies to its Alberta methanol plant.
Basic MaterialsWhat’s Led to Vulcan Materials’ Upward Dividend Yield Curve
Vulcan’s dividend yield Vulcan Materials’ (VMC) 100% dividend-per-share growth in 2016 has been followed by 25% growth in 2017. Its dividend yield curve has sloped upward due to growth in its dividend per share and a sharp drop in its stock price growth. Its stock price has risen 1% YTD (year-to-date), compared with 32% in 2016. The company, like the overall […]
Earnings ReportWhy Sanofi’s Revenues Could Fall in 3Q17
Analysts estimate Sanofi’s (SNY) revenues will fall 2.2% to 9.44 billion euros during 3Q17.
MiscellaneousSanofi Stock: Performance in 3Q17
Sanofi stock has risen ~3.9% in 3Q17. It has risen 22.5% year-to-date as of October 20, 2017.
MiscellaneousWhat Affected CAE’s Dividend Yield?
CAE (CAE) is an international frontrunner in the delivery of training for the civil aviation, defense and security, and healthcare markets.
Company & Industry OverviewsDupixent May Be Strong Growth Driver for Sanofi in the Future
Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).
Company & Industry OverviewsHow Are Novartis’s Respiratory Drugs Positioned after 1H17?
In 1H17, Novartis’s (NVS) COPD (chronic obstructive pulmonary disorder) portfolio reported revenues of around $318 million.
Company & Industry OverviewsHow TEVA’s CNS Drugs Performed in 1H17
In 1H17, Teva Pharmaceutical’s (TEVA) CNS (central nervous system) business generated revenues of ~$2.3 billion, or ~16% lower YoY (year-over-year).
Company & Industry OverviewsHow TEVA’s Generic Medicines Franchise Is Positioned after 1H17
In 1H17, Teva Pharmaceutical’s (TEVA) generic medicines business generated revenues of ~$6.1 billion, or ~22% higher YoY (year-over-year).
Energy & UtilitiesHow ONEOK Has Managed Its Impressive Dividend Yield
How ONEOK has maintained a 4% yield ONEOK (OKE), the general partner and 41% owner of ONEOK Partners, owns one of the country’s premier natural gas liquid systems. The company’s revenue grew 15% in 2016 after falling 36% in 2015. The growth was driven by its Natural Gas Gathering and Processing, Natural Gas Liquids, and […]
Company & Industry OverviewsWhat Happened to Novartis’s Innovative Medicines Business in 2Q17?
Novartis’s Innovative Medicines segment contributed over 67% of NVS’s total revenues at nearly $8.3 billion for the quarter.
IndustrialsDividend Yield of Stanley Black & Decker
Stanley Black & Decker’s (SWK) PE ratio of 21.1x is pitted against a sector average of 29.3x. The dividend yield of 1.8% is pitted against a sector average of 1.6%.
Company & Industry OverviewsNorth America: Fresenius Medical Care’s Major Target Market in 2017
In 2Q17, Fresenius Medical Care (FMS) reported revenues close to 3.3 billion euros, which represents year-over-year growth of ~11%.
Company & Industry OverviewsA Look at Sanofi Pasteur’s Performance in 2Q17
Sanofi Pasteur Sanofi Pasteur, Sanofi’s (SNY) human vaccine business, reported 26.2% revenue growth at constant exchange rates to 1.0 billion euros in 2Q17. Sanofi Pasteur reported growth across all product franchises during the quarter. Sanofi Pasteur includes polio/pertussis/Hib (haemophilus influenzae type b) vaccines, adult booster vaccines, meningitis vaccines, influenza vaccines, travel and other endemic vaccines, […]
Company & Industry OverviewsSanofi Genzyme Continues Driving Revenue Growth in 2Q17
Sanofi Genzyme In 2Q17, Sanofi Genzyme (SNY) reported revenue growth of 13.5% to 1.7 billion euros. Considering a constant structure and constant exchange rates, the growth was 14.4%. Sanofi Genzyme, which includes product revenue from the multiple sclerosis, rare disease, oncology, and immunology franchises, reported a sales increase of ~14.6% to 1.7 billion euros. This rise was […]
ConsumerKimberly-Clark’s Dividend Growth
Kimberly-Clark’s (KMB) 2016 net sales fell 2.0% due to declines in every segment.
Earnings ReportNovartis in 2Q17: Performance of Sandoz
Sandoz contributed ~20.0% of total revenues at $2.45 billion in 2Q17, a 5.0% fall compared to $2.58 billion in 2Q16.
Earnings ReportAnalysts Expect Novartis’s Revenues to Fall in 2Q17
Analysts expect Novartis’s (NVS) revenues to fall ~1.6% to $12.3 billion in 2Q17 due to the effects of the acquisition and divestiture of some of its products.
Company & Industry OverviewsInside Novartis’s Segment-Wise Performance in 1Q17
Novartis is largely exposed to currency risk, as ~50% of its total revenues are reported from international markets.
Company & Industry OverviewsPerformance of Sanofi’s Established Prescription Products in 1Q17
Revenues from Sanofi’s Established Prescription Products rose 0.6% at constant exchange rates during 1Q17 and reported revenues of ~2.6 billion euros in 1Q17.
Earnings ReportHow GlaxoSmithKline’s Vaccines Business Performed in 1Q17
GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired the meningitis and other vaccines business from Novartis (NVS).
Earnings ReportHow GlaxoSmithKline’s Business Segments Performed in 1Q17
The company reported operational growth of 5% in its revenues to 7.4 billion pounds for 1Q17.
Earnings ReportNovartis’s 1Q17 Earnings: Innovative Medicines Segment
Novartis’s (NVS) Innovative Medicines segment contributed ~66.6% to overall 1Q17 revenue, or $7.7 billion.
Earnings ReportGlaxoSmithKline’s 1Q17 Estimates: Vaccines Business
The Novartis acquisition has improved sales for GSK’s Vaccines business, mainly driven by the sales of meningitis vaccines Bexsero in Europe and Menveo in the US and Europe.
MiscellaneousAnalyst Ratings and Recommendations for Novartis
As of April 21, 2017, there are five analysts tracking Novartis. Of those, two have recommended a “strong buy,” and one has recommended a “buy.”
Earnings ReportAnalyst Estimates for Novartis’s 1Q17 Earnings
Novartis is set to release its 1Q17 earnings on April 25, 2017. Analysts estimate its 1Q17 EPS at $1.12 with revenues of ~$11.7 billion.
Company & Industry OverviewsSanofi Genzyme Continued Growth in 2016
Sanofi’s (SNY) 2016 revenues were mainly driven by Sanofi Genzyme and Sanofi Pasteur.
Company & Industry OverviewsNovartis Expects to Restore Alcon’s Profitability in the Future
Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business.
Company & Industry OverviewsReduced Co-pays May Boost Demand for Entresto
Compared to 43% at the end of 2015, Novartis’s (NVS) Entresto managed to attain a preferred formulary position in 66% of commercial plans in the US at the end of 2016.
Company & Industry OverviewsPerformance of GlaxoSmithKline’s Vaccines Business in 2016
GSK’s Vaccines business reported growth of 14% to ~4.6 billion pounds in 2016.
Company & Industry OverviewsGlaxoSmithKline’s Pharmaceuticals Segment Performance
Overall, the Pharmaceutical segment’s contribution to GSK’s total revenues was 57.7% in 2016.
Company & Industry OverviewsNovartis’s Innovative Medicines Segment in 2016
Novartis’s Innovative Medicines segment, formerly referred to as its Pharmaceuticals segment, consists of products for therapeutic areas including oncology, respiratory, and established medicines.
Company & Industry OverviewsSandoz: Novartis’s Generics Business in 2016
Sandoz, the generics arm of Novartis (NVS), is the number two generic medicines provider worldwide, and it’s number one in differentiated generics.
Company & Industry OverviewsWhat Happened to Sanofi’s Valuation after 4Q16?
On February 16, 2017, Sanofi was trading at a forward PE multiple of ~13.9x, as compared to the industry average of 15.7x.
Company & Industry OverviewsThis Keeps Driving Sanofi’s Growth
Sanofi’s (SNY) 4Q16 revenues were mainly driven by Genzyme and Sanofi Pasteur.
Company & Industry OverviewsGlaxoSmithKline’s Vaccines Business Reported Growth in 4Q16
GSK’s Vaccines segment reported a rise of 18.0% to 1.1 billion pounds in 4Q16. The Novartis acquisition has improved sales for the segment.
Company & Industry Overviews4Q16 Performance of GlaxoSmithKline’s Business Segments
Revenues for GSK’s Pharmaceuticals segment saw a shift in product performance, falling due to lower sales of its key products Seretide and Advair.
Company & Industry OverviewsNovartis’s Innovative Medicines Segment in 4Q16
The overall contribution from NVS’s Innovative Medicines segment was ~67%, reaching $8.3 billion in 4Q16.
Earnings ReportPotashCorp in 4Q16: Nitrogen Prices Added Salt to the Wound
In 4Q16, the overall average nitrogen selling price fell 37.0% to $182 per ton, from $288 per ton in 4Q15.
Earnings ReportNovartis’s 4Q16 Estimates: Innovative Medicines Segment
The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.
Company & Industry OverviewsHow Did Novartis’s Generics Business Perform in 3Q16?
Sandoz reported a decline of 1% in 3Q16 revenues at constant exchange rates.
Company & Industry OverviewsHow GlaxoSmithKline’s Pharmaceuticals Segment Has Performed
GlaxoSmithKline’s (GSK) Pharmaceuticals segment fell substantially in 2015 due to its divestment of its oncology business to Novartis (NVS) in March 2015.
Company & Industry OverviewsHow Sandoz Performed for Novartis in 3Q16
Sandoz, the generics arm of Novartis (NVS), is the number-two generic medicines provider worldwide. It’s number one in differentiated generics.
Earnings ReportHow Tresiba Helps Novo Achieve Its Growth Targets
During the first nine months of 2016, Novo’s (NVO) new generation portfolio garnered 2.8 billion Danish kroner.
Earnings ReportVictoza Dominates Global GLP-1 Class
Novo’s (NVO) Victoza is a glucagon-like peptide-1 (or GLP-1) therapy for type 2 Diabetes patients.
Earnings ReportReading Novo’s Insulin Portfolio to Find Clues about Its Growth
Novo Nordisk’s (NVO) diabetes and obesity care portfolio consists of modern insulin, Victoza, human insulin, new generation insulin, and other diabetes and obesity care products.
Earnings ReportUS Still the Largest Market for Novo Nordisk
During 3Q16, Novo’s sales in the US rose 2% in local currency terms to 14.2 billion Danish kroner.
Earnings ReportWhy Did PotashCorp’s Nitrogen Prices Fall in 3Q16?
Nitrogen selling prices PotashCorp (POT) sells nitrogen fertilizers such as ammonia, urea, and nitrogen solutions. It competes with other natural gas–based nitrogen producers such as CF Industries (CF) and Terra Nitrogen (TNH), which primarily produce and sell nitrogen fertilizers. Agrium (AGU), which is a part of the PowerShares International Dividend Achievers ETF (PID), produces nitrogen fertilizers […]
Earnings ReportHow Much Is the Return Opportunity for Novo Nordisk in 3Q16?
A Bloomberg survey of two brokerage houses on October 24, 2016, reflected a 50% “buy” rating and a 50% “hold” rating for the stock.
Earnings ReportNovartis’s 3Q16 Estimates: Will Alcon Recover Its Growth?
Alcon, Novartis’s (NVS) eye care segment, researches, develops, manufactures, and markets eye care products in over 180 countries worldwide.
Earnings ReportNovartis’s 3Q16 Estimates: Innovative Medicines Segment
Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.
Company & Industry OverviewsNovo Nordisk Is Expected to See Strong Growth in Insulin Segment
Insulin sales volumes sold across the world have grown at a compounded average growth rate (or CAGR) of 4.1% from May 2011 to May 2016.
Company & Industry OverviewsNovo Nordisk Expects to Witness Strong Growth from New Product Launches
In addition to its robust drug portfolio, Novo Nordisk boasts a strong research pipeline in the diabetes, hemophilia, obesity, and growth disorder segments.
Company & Industry OverviewsNovo Nordisk Is Focusing on These Strategic Areas in 2016
With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.
Company & Industry OverviewsTeva’s Share of the US Generics Market Could Boost Its Stock
Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.
Company & Industry OverviewsWinning? We Review How Teva Dominates Generic Drug Space
Teva Pharmaceutical Industries plans to take advantage of market dynamics and unmet demand in generic pharmaceuticals by enacting a three-pronged strategy.
Company & Industry OverviewsSanofi’s Chase for Zika Virus Vaccine Could Drive Its Share Price
Sanofi’s Vaccine segment generated 1.4 billion euros, or about $1.6 billion, during the first half of 2016.
Company & Industry OverviewsWill Sanofi See More Growth from Its Blockbuster Insulin Drug?
Sanofi’s diabetes franchise includes Lantus, Toujeo, Amaryl, and Apidra. Lantus, a glargine insulin, contributed 17% of total revenues in fiscal 2015.
Company & Industry OverviewsGSK Optimistic about Future of Its Consumer Healthcare Segment
With improvements in the supply chain and successful launch of new products, GlaxoSmithKline (GSK) is optimistic about its consumer healthcare segment performance.
Company & Industry OverviewsGlaxoSmithKline Giving a Shot to Its Vaccines Business
GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired Novartis’s (NVS) meningitis and other vaccines business.
Company & Industry OverviewsGlaxoSmithKline’s Combo Treatment for HIV Faces Stiff Competition
GlaxoSmithKline’s (GSK) HIV medicines business is managed by ViiV Healthcare, a global specialist company in HIV medicines.
Company & Industry OverviewsAnalyzing Sanofi’s Asset Swap Deal with Boehringer Ingelheim
Sanofi is swapping its animal health business with Boehringer Ingelheim’s consumer healthcare business. The asset swap deal was signed on June 27, 2016.
Company & Industry OverviewsTeva Pharmaceutical: A Successful Bond Financing Program in 2016
To finance the acquisition of Allergan Generics (AGN), Teva Pharmaceutical (TEVA) successfully completed a global bond offering on July 21, 2016.
Company & Industry OverviewsHow Merial Contributes to Sanofi’s Growth
Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.
Company & Industry OverviewsWhat Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16?
Sanofi’s Consumer Healthcare segment includes Allegra, Doliprane, Nasacort, and other products. It reported a 4.3% decline in revenues to 800 million euros.
Company & Industry OverviewsBehind Sanofi’s Diabetes and Cardiovascular Performance in 2Q16
Sanofi’s Diabetes and Cardiovascular revenues declined by ~2% at constant exchange rates to 1.96 billion euros (about $2.21 billion) in 2Q16.
Company & Industry OverviewsGenzyme Continued to Boost Growth for Sanofi in 2Q16
After Sanofi’s reorganization, Genzyme now includes products for multiple sclerosis, rare diseases, and oncology. Genzyme’s sales increased ~19.5% in 2Q16.
Company & Industry OverviewsInside Sanofi’s Valuation Changes
With rising sales of in its Genzyme, Animal Health, and Vaccines segments, Sanofi has reported a growing top line over the past few quarters.
Earnings ReportHow Did Novo Nordisk Perform across Geographies in 1H16?
As of May 2016, Novo Nordisk (NVO) held a 46% share of the global total insulin market.
Earnings ReportAn Update on Shire’s Upcoming Milestones
Shire anticipates receiving European Union approval for Natpara for the indication of hyperparathyroidism in 4Q16.
Earnings ReportHow Much Growth Will Novo See in 2Q16?
Following a company press release, Novo Nordisk (NVO) will announce earnings for the second quarter of 2016 on August 5, 2016.
Earnings ReportHow Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 2Q16?
GlaxoSmithKline’s (GSK) Pharmaceuticals segment declined substantially in 2015 due to the divestment of its oncology business to Novartis (NVS) in March 2015.
Earnings ReportGlaxoSmithKline Increases Top Line in 2Q16
GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.
Earnings ReportWhat to Expect from Shire’s Genetic Disease Franchise
Wall Street analysts expect Elaprase to earn $145.6 million in 2Q16 and $140.5 million in 3Q16.
Earnings ReportNovartis’s 2Q16 Earnings: What’s Expected?
Analysts have given Novartis’s stock a 12-month target price of $92.50 per share, as compared to the last closing price of $81.61 per share on July 15.
Company & Industry OverviewsHow Could the Novartis-Xencor Alliance Benefit Novartis?
As we’ve discussed, Novartis (NVS) is one of the largest pharmaceutical companies by revenue.
Company & Industry OverviewsWhat Is Xencor’s XmAb Technology?
The XmAb antibody engineering platform is Xencor’s proprietary technology.
Company & Industry OverviewsEvaluating Novo Nordisk’s Efficiency Based on EV-to-EBITDA
On June 23, 2016, Novo Nordisk (NVO) was trading at a forward EV-to-EBITDA multiple of 14.14x. It was trading at a premium compared to its peers.
Company & Industry OverviewsHow Shire’s Robust Pipeline Could Drive Its Valuation
With the completion of the Baxalta acquisition, Shire (SHPG) has 50 inline and pipeline products and programs.
Company & Industry OverviewsSanofi’s Diabetes and Cardiovascular Franchise Performance
Sanofi’s (SNY) Cardiovascular franchise includes Praluent and Multaq. Praluent, an injection for lowering LDL cholesterol, was launched in collaboration with Regeneron in July 2015 in the US markets, where it reported sales of 9 million euros in 1Q16.